We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$316M
Cap. Flow
-$376M
Cap. Flow %
-51.38%
Top 10 Hldgs %
46.9%
Holding
119
New
21
Increased
21
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$26M
2
INSM icon
Insmed
INSM
+$25.6M
3
TRVI icon
Trevi Therapeutics
TRVI
+$7.99M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.57M
5
VTYX
Ventyx Biosciences
VTYX
+$7.33M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$17.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.8M
3
MRUS
Merus
MRUS
+$11.8M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$8.19M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$7.44M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
101
MeiraGTx Holdings
MGTX
$1.12B
– –
-150,000
Closed -$1.02M
MLYS icon
102
PUT
Mineralys Therapeutics
MLYS
$2.38B
– –
-200,000
Closed -$3.18M
NAMS icon
103
CALL
NewAmsterdam Pharma
NAMS
$3.57B
– –
-99,800
Closed -$2.04M
NAMS icon
104
PUT
NewAmsterdam Pharma
NAMS
$3.57B
– –
-75,000
Closed -$1.54M
NBIX icon
105
Neurocrine Biosciences
NBIX
$17.5B
– –
-50,000
Closed -$5.53M
OMER icon
106
Omeros
OMER
$744M
– –
-9,958
Closed -$49.6K
PTGX icon
107
CALL
Protagonist Therapeutics
PTGX
$8.71B
– –
-172,500
Closed -$8.34M
SLNO
108
DELISTED
Soleno Therapeutics
SLNO
– –
-50,000
Closed -$3.57M
SPY icon
109
State Street SPDR S&P 500 ETF Trust
SPY
$777B
– –
-30,000
Closed -$16.8M
SPY icon
110
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
– –
-400,000
Closed -$224M
TRML
111
CALL
DELISTED
Tourmaline Bio
TRML
– –
-100,000
Closed -$1.52M
VERA icon
112
CALL
Vera Therapeutics
VERA
$2.61B
– –
-265,000
Closed -$6.37M
VKTX icon
113
Viking Therapeutics
VKTX
$4.11B
– –
-25,000
Closed -$604K
XBI icon
114
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
– –
-500,000
Closed -$40.5M
MBX
115
MBX Biosciences
MBX
$3.03B
– –
-175,000
Closed -$1.29M
MAZE
116
Maze Therapeutics
MAZE
$1.53B
– –
-250,000
Closed -$2.75M
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Affinity Asset Advisors held 119 positions worth $732M, down 30% from $1.05B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $376M in Q2 2025, closing 28 positions and reducing 25 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 55% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Blueprint Medicines worth $32M.

  • Affinity Asset Advisors's largest Q2 2025 buy was Blueprint Medicines: 250,000 shares worth $32M.
  • Affinity Asset Advisors added most to Insmed in Q2 2025, an estimated $25.6M increase.
  • Affinity Asset Advisors's biggest Q2 2025 reduction was Apogee Therapeutics, cutting an estimated $17.5M.
  • Affinity Asset Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q2 2025, selling an estimated $16.8M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $732M portfolio in Q2 2025.
  • Affinity Asset Advisors opened 21 new positions and closed 28 in Q2 2025.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $732M.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.